Filing Flows › Crispr Therapeutics AG (CRSP) › Q3 2026 › vs Q3 2025
Crispr Therapeutics AG (CRSP) Q3 2026 vs Q3 2025 (year over year)
Crispr Therapeutics AG's revenue rose $11.8M (14×) from $889K in Q3 2025 to $12.7M in Q3 2026. The biggest changes: Collaboration Revenue +$12.3M (—); Grant −$543K (-61%).
Crispr Therapeutics AG, Q3 2026: revenue $12.7M (14× year over year), net loss $111M, operating cash flow −$89.7M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Collaboration Revenue | $12.3M | $0 | $12.3M | — |
| Grant | $346K | $889K | −$543K | -61% |
| Revenue | $12.7M | $889K | $11.8M | 14× |
| Other income, net | $18.7M | $26.2M | −$7.6M | -29% |
| Net loss | $111M | $106M | $5.0M | +5% |
| Costs & expenses | $143M | $134M | $9.2M | +7% |
| Operating costs | $143M | $133M | $9.8M | +7% |
| Income tax | $74K | $619K | −$545K | -88% |
| Research & development | $71.9M | $58.9M | $13.0M | +22% |
| General & admin | $17.9M | $16.9M | $936K | +6% |
| Other operating costs | $53.0M | $57.1M | −$4.2M | -7% |
| Operating cash sources | $112M | $106M | $6.2M | +6% |
| Depreciation & amortization | $4.2M | $4.4M | −$195K | -4% |
| Share-based compensation | $18.0M | $16.6M | $1.4M | +8% |
| Cash used in operations | $89.7M | $84.6M | $5.0M | +6% |
| Net loss absorbed | $111M | $106M | $5.0M | +5% |
| Working capital & other | $446K | −$770K | $1.2M | — |
Questions
How much did Crispr Therapeutics AG's revenue grow year over year in Q3 2026?
Crispr Therapeutics AG's revenue rose $11.8M (14×) from $889K in Q3 2025 to $12.7M in Q3 2026.
What drove Crispr Therapeutics AG's revenue change in Q3 2026?
Collaboration Revenue +$12.3M (—); Grant −$543K (-61%).